Trial Review

ANZCTR is currently experiencing a technical issue. Thank you for your patience while we work on it and apologies for any inconvenience caused.


Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements.
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06455202




Registration number
NCT06455202
Ethics application status
Date submitted
7/06/2024
Date registered
12/06/2024
Date last updated
28/05/2025

Titles & IDs
Public title
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
Scientific title
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU2)
Secondary ID [1] 0 0
2024-513210-36-00
Secondary ID [2] 0 0
CDX0159-13
Universal Trial Number (UTN)
Trial acronym
EMBARQ-CSU2
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Spontaneous Urticaria 0 0
Condition category
Condition code
Skin 0 0 0 0
Dermatological conditions
Skin 0 0 0 0
Other skin conditions
Inflammatory and Immune System 0 0 0 0
Allergies
Inflammatory and Immune System 0 0 0 0
Autoimmune diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - barzolvolimab
Treatment: Other - Matching placebo

Experimental: barzolvolimab 150 mg - barzolvolimab given once as a 300 mg subcutaneous injection followed by 150 mg administered every 4 weeks for 52 weeks

Experimental: barzolvolimab 300 mg - barzolvolimab given once as a 450 mg subcutaneous injection followed by 300 mg administered every 8 weeks for 52 weeks

Experimental: Placebo then barzolvolimab 150 mg - Placebo injection subcutaneous every 4 weeks for 24 weeks and then barzolvolimab 300 mg followed by 150 mg administered every 4 weeks for 28 weeks.

Experimental: Placebo then barzolvolimab 300 mg - Placebo injection subcutaneous every 4 weeks for 24 weeks and then barzolvolimab 450 mg followed by 300 mg administered every 8 weeks for 28 weeks.


Treatment: Other: barzolvolimab
Subcutaneous Administration

Treatment: Other: Matching placebo
Matching placebo Subcutaneous Administration
Intervention code [1] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Mean change from baseline to Week 12 of UAS7 (Urticaria Activity Score)
Timepoint [1] 0 0
From Day 1 (first dose) to Day 85 (Week 12)
Secondary outcome [1] 0 0
Mean change from baseline to Week 12 of ISS7 (Itch Severity Score)
Timepoint [1] 0 0
From Day 1 (first dose) to Day 85 (Week 12)
Secondary outcome [2] 0 0
Mean change from baseline to Week 12 of HSS7 (Hives Severity Score)
Timepoint [2] 0 0
From Day 1 (first dose) to Day 85 (Week 12)
Secondary outcome [3] 0 0
Percentage of patients with UAS7=0 at Week 12
Timepoint [3] 0 0
From Day 1 (first dose) to Day 85 (Week 12)
Secondary outcome [4] 0 0
Mean change from baseline in UAS7 in participants refractory to omalizumab treatment at Week 12
Timepoint [4] 0 0
From Day 1 (first dose) to Day 85 (Week 12)
Secondary outcome [5] 0 0
Proportion of participants with UAS7 = 0 in participants refractory to omalizumab treatment at Week 12
Timepoint [5] 0 0
From Day 1 (first dose) to Day 85 (Week 12)
Secondary outcome [6] 0 0
Percentage of participants with UAS7 = 6 at Week 12
Timepoint [6] 0 0
From Day 1 (first dose) to Day 85 (Week 12)
Secondary outcome [7] 0 0
Mean change from baseline in UAS7 at Week 4
Timepoint [7] 0 0
From Day 1 (first dose) to Day 29 (Week 4)
Secondary outcome [8] 0 0
Mean change from baseline in UAS7 at Week 24
Timepoint [8] 0 0
From Day 1 (first dose) to Day 169 (Week 24)
Secondary outcome [9] 0 0
Percentage of participants with UAS7 = 0 at Week 24
Timepoint [9] 0 0
From Day 1 (first dose) to Day 169 (Week 24)
Secondary outcome [10] 0 0
Incidence of Treatment-Emergent Adverse Events
Timepoint [10] 0 0
From Day 1 (first dose) to Day 477 (Week 68)

Eligibility
Key inclusion criteria
Key

1. Males and females, >/= 18 years of age.
2. Chronic spontaneous urticaria (CSU) >/= 6 months prior to Screening (Visit 1).
3. CSU despite the use of a stable regimen of second generation non-sedating H1-antihistamine as defined by:

1. The presence of hives for >/= 6 weeks at any time prior to Visit 1 despite the use of non-sedating H1-antihistamines.
2. Must be on a stable regimen of second generation non-sedating H1-antihistamine for >/= 4 weeks prior to study treatment.
3. UAS7 of >/= 16 and ISS7 of >/= 8 during the 7 days prior to study treatment.
4. Normal blood counts and liver function tests.
5. Both males and females of child-bearing potential must agree to use highly effective contraceptives during the study and for 150 days after treatment.
6. Willing and able to complete a daily symptom electronic diary and comply with study visits.
7. Participants with and without prior biologic experience are eligible.

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Women who are pregnant or nursing.
2. Chronic urticaria whose predominant manifestation is due to CIndU.
3. Other diseases associated with urticaria.
4. Active pruritic skin condition in addition to CSU.
5. Medical condition that would cause additional risk or interfere with study procedures.
6. Known HIV, hepatitis B or hepatitis C infection.
7. Vaccination of a live vaccine within 30 days prior to Screening (Visit 1) (subjects must agree to avoid live vaccinations during the study). Inactivated vaccines are allowed such as seasonal influenza injection or authorized COVID-19 vaccine.
8. History of anaphylaxis
9. Prior treatment with barzolvolimab

There are additional criteria that your study doctor will review with you to confirm you are eligible for the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
19/07/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/04/2027
Actual
Sample size
Target
915
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
Skin and Cancer Foundation - The Skin Hospital - Darlinghurst
Recruitment hospital [2] 0 0
St George Dermatology and Skin Cancer Center - Kogarah
Recruitment hospital [3] 0 0
Novatrials - Kotara
Recruitment hospital [4] 0 0
Momentum Clinical Research Darlinghurst - Sydney
Recruitment hospital [5] 0 0
Westmead Hospital - Westmead
Recruitment hospital [6] 0 0
Princess Alexandra Hospital - Brisbane
Recruitment hospital [7] 0 0
Cornerstone Dermatology - Coorparoo
Recruitment hospital [8] 0 0
Veracity Clinical Research Pty Ltd - Woolloongabba
Recruitment hospital [9] 0 0
Box Hill Hospital - Box Hill
Recruitment hospital [10] 0 0
Dr Rodney Sinclair Pty Ltd - East Melbourne
Recruitment hospital [11] 0 0
The Alfred Hospital - Melbourne
Recruitment hospital [12] 0 0
The Royal Melbourne Hospital - Parkville
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
2217 - Kogarah
Recruitment postcode(s) [3] 0 0
2289 - Kotara
Recruitment postcode(s) [4] 0 0
2010 - Sydney
Recruitment postcode(s) [5] 0 0
2145 - Westmead
Recruitment postcode(s) [6] 0 0
4102 - Brisbane
Recruitment postcode(s) [7] 0 0
4151 - Coorparoo
Recruitment postcode(s) [8] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [9] 0 0
3128 - Box Hill
Recruitment postcode(s) [10] 0 0
3002 - East Melbourne
Recruitment postcode(s) [11] 0 0
3004 - Melbourne
Recruitment postcode(s) [12] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Colorado
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Idaho
Country [9] 0 0
United States of America
State/province [9] 0 0
Indiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Kansas
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Michigan
Country [15] 0 0
United States of America
State/province [15] 0 0
Missouri
Country [16] 0 0
United States of America
State/province [16] 0 0
Nebraska
Country [17] 0 0
United States of America
State/province [17] 0 0
New Jersey
Country [18] 0 0
United States of America
State/province [18] 0 0
New York
Country [19] 0 0
United States of America
State/province [19] 0 0
Ohio
Country [20] 0 0
United States of America
State/province [20] 0 0
Rhode Island
Country [21] 0 0
United States of America
State/province [21] 0 0
Texas
Country [22] 0 0
United States of America
State/province [22] 0 0
Utah
Country [23] 0 0
United States of America
State/province [23] 0 0
Virginia
Country [24] 0 0
Bulgaria
State/province [24] 0 0
Dupnitsa
Country [25] 0 0
Bulgaria
State/province [25] 0 0
Haskovo
Country [26] 0 0
Bulgaria
State/province [26] 0 0
Lovech
Country [27] 0 0
Bulgaria
State/province [27] 0 0
Pazardzhik
Country [28] 0 0
Bulgaria
State/province [28] 0 0
Ruse
Country [29] 0 0
Bulgaria
State/province [29] 0 0
Sevlievo
Country [30] 0 0
Bulgaria
State/province [30] 0 0
Sofia
Country [31] 0 0
Canada
State/province [31] 0 0
Alberta
Country [32] 0 0
Canada
State/province [32] 0 0
Ontario
Country [33] 0 0
Canada
State/province [33] 0 0
Saskatchewan
Country [34] 0 0
Canada
State/province [34] 0 0
Québec
Country [35] 0 0
Chile
State/province [35] 0 0
Lo Barnechea
Country [36] 0 0
Chile
State/province [36] 0 0
Providencia
Country [37] 0 0
Chile
State/province [37] 0 0
Recoleta
Country [38] 0 0
Chile
State/province [38] 0 0
Santiago
Country [39] 0 0
Chile
State/province [39] 0 0
Vitacura
Country [40] 0 0
Colombia
State/province [40] 0 0
Medellin
Country [41] 0 0
Colombia
State/province [41] 0 0
Medellín
Country [42] 0 0
Colombia
State/province [42] 0 0
Soledad
Country [43] 0 0
Georgia
State/province [43] 0 0
Tbilisi
Country [44] 0 0
Germany
State/province [44] 0 0
Aachen
Country [45] 0 0
Germany
State/province [45] 0 0
Bad Bentheim
Country [46] 0 0
Germany
State/province [46] 0 0
Berlin
Country [47] 0 0
Germany
State/province [47] 0 0
Bonn
Country [48] 0 0
Germany
State/province [48] 0 0
Dresden
Country [49] 0 0
Germany
State/province [49] 0 0
Düsseldorf
Country [50] 0 0
Germany
State/province [50] 0 0
Essen
Country [51] 0 0
Germany
State/province [51] 0 0
Hamburg
Country [52] 0 0
Germany
State/province [52] 0 0
Lübeck
Country [53] 0 0
Germany
State/province [53] 0 0
Münster
Country [54] 0 0
Germany
State/province [54] 0 0
Remscheid
Country [55] 0 0
Germany
State/province [55] 0 0
Tübingen
Country [56] 0 0
Hungary
State/province [56] 0 0
Debrecen
Country [57] 0 0
Hungary
State/province [57] 0 0
Szolnok
Country [58] 0 0
India
State/province [58] 0 0
Gujarat
Country [59] 0 0
India
State/province [59] 0 0
Maharashtra
Country [60] 0 0
India
State/province [60] 0 0
Rajasthan
Country [61] 0 0
India
State/province [61] 0 0
Uttar Pradesh
Country [62] 0 0
India
State/province [62] 0 0
Ahmedabad
Country [63] 0 0
India
State/province [63] 0 0
Belgaum
Country [64] 0 0
India
State/province [64] 0 0
Mysore
Country [65] 0 0
India
State/province [65] 0 0
Pune
Country [66] 0 0
India
State/province [66] 0 0
Vadodara
Country [67] 0 0
Italy
State/province [67] 0 0
Genova
Country [68] 0 0
Italy
State/province [68] 0 0
Milano
Country [69] 0 0
Italy
State/province [69] 0 0
Rozzano
Country [70] 0 0
Italy
State/province [70] 0 0
Salerno
Country [71] 0 0
Italy
State/province [71] 0 0
San Donato Milanese
Country [72] 0 0
Lithuania
State/province [72] 0 0
Kaunas
Country [73] 0 0
Lithuania
State/province [73] 0 0
Vilnius
Country [74] 0 0
Netherlands
State/province [74] 0 0
Amsterdam
Country [75] 0 0
Netherlands
State/province [75] 0 0
Roosendaal
Country [76] 0 0
Netherlands
State/province [76] 0 0
Utrecht
Country [77] 0 0
Poland
State/province [77] 0 0
Czestochowa
Country [78] 0 0
Poland
State/province [78] 0 0
Elblag
Country [79] 0 0
Poland
State/province [79] 0 0
Gdansk
Country [80] 0 0
Poland
State/province [80] 0 0
Grodzisk Mazowiecki
Country [81] 0 0
Poland
State/province [81] 0 0
Kraków
Country [82] 0 0
Poland
State/province [82] 0 0
Lublin
Country [83] 0 0
Poland
State/province [83] 0 0
Oswiecim
Country [84] 0 0
Poland
State/province [84] 0 0
Poznan
Country [85] 0 0
Poland
State/province [85] 0 0
Rzeszów
Country [86] 0 0
Poland
State/province [86] 0 0
Tarnów
Country [87] 0 0
Poland
State/province [87] 0 0
Warszawa
Country [88] 0 0
Slovakia
State/province [88] 0 0
Bardejov
Country [89] 0 0
Slovakia
State/province [89] 0 0
Bratislava
Country [90] 0 0
Slovakia
State/province [90] 0 0
Košice
Country [91] 0 0
Spain
State/province [91] 0 0
Barcelona
Country [92] 0 0
Spain
State/province [92] 0 0
Cadiz
Country [93] 0 0
Spain
State/province [93] 0 0
Madrid
Country [94] 0 0
Spain
State/province [94] 0 0
Pamplona
Country [95] 0 0
Spain
State/province [95] 0 0
Pontevedra
Country [96] 0 0
Spain
State/province [96] 0 0
Pozuelo De Alarcón
Country [97] 0 0
Spain
State/province [97] 0 0
Sevilla
Country [98] 0 0
Spain
State/province [98] 0 0
Torrejón De Ardoz
Country [99] 0 0
Spain
State/province [99] 0 0
Valencia
Country [100] 0 0
Thailand
State/province [100] 0 0
Bangkok Noi
Country [101] 0 0
Thailand
State/province [101] 0 0
Chiang Mai
Country [102] 0 0
Thailand
State/province [102] 0 0
Khlong Luang
Country [103] 0 0
Thailand
State/province [103] 0 0
Khon Kaen
Country [104] 0 0
United Kingdom
State/province [104] 0 0
Cambridge
Country [105] 0 0
United Kingdom
State/province [105] 0 0
Glasgow
Country [106] 0 0
United Kingdom
State/province [106] 0 0
Leeds
Country [107] 0 0
United Kingdom
State/province [107] 0 0
London
Country [108] 0 0
United Kingdom
State/province [108] 0 0
North Finchley
Country [109] 0 0
United Kingdom
State/province [109] 0 0
Oxford
Country [110] 0 0
United Kingdom
State/province [110] 0 0
Plymouth

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Celldex Therapeutics
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Celldex Therapeutics
Address 0 0
Country 0 0
Phone 0 0
844-723-9363
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries

Data sharing statement


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT06455202